KLK3 and prostate carcinoma: To determine the cost implications of a reduction in the false positive rate for a new theoretical prostate cancer screening test, we used a false positive proportion of 42.1% for PSA screening (assuming a cutoff of 4 ng/ml is used to determine patients who receive biopsy) [20].